Universität zu Köln

Marnitz, S., Schermeyer, L., Dommerich, S., Koehler, C., Olze, H., Budach, V. and Martus, P. (2018). Age-corrected hearing loss after chemoradiation in cervical cancer patients. Strahlenther. Onkol., 194 (11). S. 1039 - 1049. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

Full text not available from this repository.

Abstract

Objective This study aimed to evaluate subjective and objective hearing loss in cervical cancer patients after chemoradiation with cisplatin (mono). Patients and methods A total of 51 cervical cancer patients with indication for chemoradiation were included. Pure tone and impedance audiometry were performed before and after chemoradiation. Hearing loss was scaled according to ASHA criteria. Subjective hearing was assessed with the Oldenburger Sentence Test. To consider age-dependent changes, hearing loss was corrected for age and the time interval between measurements. Results Median age at diagnosis was 46 years, 46% were active/former smokers (n=24), 28 (54%) patients were never-smokers. Median total weekly cisplatin dose was 70 +/- 14.2mg. Cumulative doses of cisplatin during chemoradiation ranged between 115.2 and 400mg cisplatin (mean 336.1mg, median 342 +/- 52.7mg). The median interval between last chemotherapy and second audiometry was 320 +/- 538 days (35-2262 days). Changes in hearing threshold >= 20dB were experienced by 32/52 patients (62%) following chemoradiation, 55% of them for frequencies >= 6000Hz. No statistically significant hearing loss remained after chemoradiation upon correction for age and time interval. Patients >40 years had a higher risk of hearing loss than younger patients. Objective data on hearing function did not correlate with subjective hearing loss and did not impair daily activity in any patient. Conclusion Chemoradiation with cumulative cisplatin doses up to 400mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Marnitz, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schermeyer, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dommerich, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Olze, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Budach, V. UNSPECIFIED UNSPECIFIED UNSPECIFIED Martus, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-167376
DOI:	10.1007/s00066-018-1347-6
Journal or Publication Title:	Strahlenther. Onkol.
Volume:	194
Number:	11
Page Range:	S. 1039 - 1049
Date:	2018
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1439-099X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CISPLATIN-INDUCED OTOTOXICITY; GYNECOLOGIC-ONCOLOGY-GROUP; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; PELVIC RADIATION; RANDOMIZED-TRIAL; FOLLOW-UP; RADIOTHERAPY; HYDROXYUREA; PREVENTION Multiple languages Oncology; Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16737